Clinical Trial Update: Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of XRP0038/NV1FGF in patients with critical limb ischemia and skin lesions; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Arterial Disease

Drugs mentioned

• XRP0038/NV1FGF

Snippet

Sponsor: Sanofi | Conditions: Peripheral Vascular Diseases | Phase 3 | Status: COMPLETED